David E. Wheadon bought $63k of INDV
director at Indivior Pharmaceuticals, Inc.. 1,771 shares at an average of $35.39, traded Jan 5, 2026, filed Jan 7, 2026.
Score components
- +15RoleDirector
- +8Trade size$63k at market
- +3Relative to holdingsHoldings up 14%
- 0Price contextNo price history yet
- +15Cluster5 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -1510b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -4.3%, 3m -11.0%, 6m +13.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001789507-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 5, 2026 | POpen-market purchase Ordinary Shares10b5-1 | +1,771 | $35.39 | $63k | 14,395 | Jan 7, 2026 |
Related signals
Other insiders at Indivior Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 34Weak | INDVbuy Indivior Pharmaceuticals, Inc. | Woodrow D Anderson Chief Accounting Officer | $54k 1,500 shares | +6% | |
| 25Weak | INDVbuy Indivior Pharmaceuticals, Inc. | Woodrow D Anderson Chief Accounting Officer | $54k 1,500 shares | +6% | |
| 17Weak | Indivior Pharmaceuticals, Inc. | Christian Heidbreder Chief Scientific Officer | $765k 18,586 shares | -8% | |
| 24Weak | Indivior Pharmaceuticals, Inc. | Christian Heidbreder Chief Scientific Officer | $707k 18,586 shares | -8% | |
| 40Moderate | Indivior Pharmaceuticals, Inc. | Ryan Preblick Chief Financial Officer | $1.4M 36,000 shares | -11% | |
| 23Weak | Indivior Pharmaceuticals, Inc. | Barbara Ryan director | $249 8 shares | +0% | |
| 34Weak | Indivior Pharmaceuticals, Inc. | Stuart A Kingsley director | $30k 940 shares | +20% | |
| 23Weak | Indivior Pharmaceuticals, Inc. | Barbara Ryan director | $1,009 31 shares | +1% | |
| 23Weak | Indivior Pharmaceuticals, Inc. | Keith Humphreys director | $27k 775 shares | +15% | |
| 20Weak | Indivior Pharmaceuticals, Inc. | Daniel A Ninivaggi director | $27k 775 shares | +5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.